Evidence map›Paper›PMID 28335828›Full record

ArticleAlzheimer's research & therapy2017

DHA brain uptake and APOE4 status: a PET study with [1-

Hussein N Yassine, Etienne Croteau, Varun Rawat, Joseph R Hibbeln, Stanley I Rapoport, Stephen C Cunnane, John C Umhau

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. The physiological effects of APOE genotype in healthy young/middle-aged individuals.Biological reviews of the Cambridge Philosophical Society · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Effects of APOE4 on omega-3 brain metabolism across the lifespan.Trends in endocrinology and metabolism: TEM · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Synthesis and Preclinical Evaluation of 22-[ACS chemical neuroscience · 2023
    Article
  19. Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Hussein N YassineDepartment of Medicine, University of Southern California, 2250 Alcazar Street, Room 210, Los Angeles, CA, 90033, USA. hyassine@usc.edu.
Etienne CroteauResearch Center on Aging, University of Sherbrooke, Sherbrooke, QC, Canada.
Varun RawatDepartment of Medicine, University of Southern California, 2250 Alcazar Street, Room 210, Los Angeles, CA, 90033, USA.
Joseph R HibbelnSection on Nutritional Neurosciences, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.
Stanley I RapoportBrain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Stephen C CunnaneResearch Center on Aging, University of Sherbrooke, Sherbrooke, QC, Canada.
John C UmhauSection on Nutritional Neurosciences, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.
Université de Sherbrooke · CAUniversity of Southern California · USCenter for Drug Evaluation and Research · USNational Institute on Aging · USNational Institutes of Health · US

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KIM, PAUL E · 1985 to 2019
$41.0M
Nutritional Effects On Essential Fatty Acid CompositionZIAAA000235 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI HIBBELN, JOSEPH · 2009 to 2020
$8.2M
Essential Fatty Acids In Psychiatric DisordersZIAAA000115 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI HIBBELN, JOSEPH · 2009 to 2020
$7.8M
The delivery of essential fatty acids to the Brain in Alzheimer's diseaseR01AG054434 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$5.4M
The Effect of Saturated Fat Ingestion on the HDL ProteomeK23HL107389 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2012 to 2016
$648k
NHLBI NIH HHS K23 HL107389NIA NIH HHS P50 AG005142NIA NIH HHS R01 AG054434
6 · The paper itself

Abstract

backgroundThe apolipoprotein E ɛ4 (APOE4) allele is the strongest genetic risk factor identified for developing Alzheimer's disease (AD). Among brain lipids, alteration in the ω-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) homeostasis is implicated in AD pathogenesis. APOE4 may influence both brain DHA metabolism and cognitive outcomes.

methodsUsing positron emission tomography, regional incorporation coefficients (k*), rates of DHA incorporation from plasma into the brain using [1-

resultsThe mean global gray matter DHA incorporation coefficient, k*, was significantly higher (16%) among APOE4 carriers (n = 9) than among noncarriers (n = 13, p = 0.046). Higher DHA incorporation coefficients were observed in several brain regions, particularly in the entorhinal subregion, an area affected early in AD pathogenesis. Cerebral blood flow, unesterified plasma DHA, and whole brain DHA incorporation rate (J

conclusionsOur findings suggest an increase in the DHA incorporation coefficient in several brain regions in APOE4 carriers. These findings may contribute to understanding how APOE4 genotypes affect AD risk.

Indexed as

AdultAgedApolipoprotein E4BrainCarbon RadioisotopesDocosahexaenoic AcidsFemaleHumansMaleMetabolic Clearance RateMiddle AgedMolecular ImagingPositron-Emission TomographyRadiopharmaceuticalsReference ValuesTissue DistributionApolipoprotein E4Carbon RadioisotopesDocosahexaenoic AcidsRadiopharmaceuticalsAlzheimer’s diseaseAPOEDHAPET

Identifiers

PMID28335828
PMCPMC5364667
OpenAlexW2600216530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.